[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fm8A5b9cFKboDS7nbD78p_DWGJruJDrqz7mXumQDc2fo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":43,"rows":50},"Corporacion Parc Tauli",[4],162,false,16,3,57968,2,142,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Critical Illness",8,{"name":18,"count":19},"Mechanical Ventilation Complication",4,{"name":21,"count":9},"Inflammatory Bowel Diseases",{"name":23,"count":9},"Ulcerative Colitis",{"name":25,"count":9},"Crohn Disease",{"name":27,"count":9},"COVID-19",{"name":29,"count":9},"Fatigue",{"name":31,"count":9},"Colon Cancer",[33,38],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06840652","Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption","2026-01","Baclofen",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06450574","Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)","2026-10","Capecitabine",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,88,115,140,167,195,213,231,260,278,307,325,343,361,379,406,431,449,475,493,519,543,566,594,612,639,664,689,713],{"intervention":42,"totalTrials":11,"cells":52},{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":60,"PHASE4":84,"NA":86},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":55},[],{"trials":61,"activeCount":83,"soonestReadout":41},[62,71],{"nctId":39,"briefTitle":40,"status":63,"phases":64,"primaryCompletion":41,"completion":65,"start":66,"enrollment":67,"conditions":68,"interventions":70},"NOT_YET_RECRUITING",[47],"2027-10","2024-10",106,[69],"Rectal Cancer Stage I",[42],{"nctId":72,"briefTitle":73,"status":74,"phases":75,"primaryCompletion":76,"completion":77,"start":78,"enrollment":79,"conditions":80,"interventions":82},"NCT01308190","Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer","COMPLETED",[47],"2017-12","2021-10","2010-08",173,[81],"Rectal Cancer",[42],1,{"trials":85,"activeCount":55},[],{"trials":87,"activeCount":55},[],{"intervention":37,"totalTrials":83,"cells":89},{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":98,"NA":100},{"trials":91,"activeCount":55},[],{"trials":93,"activeCount":55},[],{"trials":95,"activeCount":55},[],{"trials":97,"activeCount":55},[],{"trials":99,"activeCount":55},[],{"trials":101,"activeCount":83,"soonestReadout":36},[102],{"nctId":34,"briefTitle":35,"status":103,"phases":104,"primaryCompletion":36,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":114},"ENROLLING_BY_INVITATION",[],"2026-07","2022-12-22",120,[109,110,111,112,113],"Alcoholic Cirrhosis","Alcohol Abstinence","Alcohol Withdrawal","Medication Toxicity","Medication Adherence",[37],{"intervention":116,"totalTrials":83,"cells":117},"Growth hormone",{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":138},{"trials":119,"activeCount":55},[],{"trials":121,"activeCount":55},[],{"trials":123,"activeCount":55},[],{"trials":125,"activeCount":55},[],{"trials":127,"activeCount":55},[128],{"nctId":129,"briefTitle":130,"status":74,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT03616509","GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition",[48],"2019-07-26","2017-06-19",30,[136],"Prader-Willi Syndrome",[116],{"trials":139,"activeCount":55},[],{"intervention":141,"totalTrials":83,"cells":142},"Indocyanine green",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":165},{"trials":144,"activeCount":55},[],{"trials":146,"activeCount":55},[],{"trials":148,"activeCount":55},[],{"trials":150,"activeCount":55},[],{"trials":152,"activeCount":55},[153],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":164},"NCT05709548","Use of Indocyanine Green in Acute Cholecystitis","UNKNOWN",[48],"2025-12","2023-03-15",440,[162,163],"Acute Cholecystitis","Bile Duct Injury",[141],{"trials":166,"activeCount":55},[],{"intervention":168,"totalTrials":83,"cells":169},"Ibuprofen",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":193},{"trials":171,"activeCount":55},[],{"trials":173,"activeCount":55},[],{"trials":175,"activeCount":55},[],{"trials":177,"activeCount":55},[],{"trials":179,"activeCount":55},[180],{"nctId":181,"briefTitle":182,"status":74,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":190},"NCT02785549","Randomized Clinical Trial to Compare the Treatment of Mild Acute Diverticulitis With or Without Antibiotics",[48],"2020-01-12","2020-04-01","2016-11",480,[189],"Acute Diverticulitis",[168,191,192],"Acetaminophen","Amoxicillin\u002Fclavulanic acid",{"trials":194,"activeCount":55},[],{"intervention":191,"totalTrials":83,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":211},{"trials":198,"activeCount":55},[],{"trials":200,"activeCount":55},[],{"trials":202,"activeCount":55},[],{"trials":204,"activeCount":55},[],{"trials":206,"activeCount":55},[207],{"nctId":181,"briefTitle":182,"status":74,"phases":208,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":209,"interventions":210},[48],[189],[168,191,192],{"trials":212,"activeCount":55},[],{"intervention":192,"totalTrials":83,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":229},{"trials":216,"activeCount":55},[],{"trials":218,"activeCount":55},[],{"trials":220,"activeCount":55},[],{"trials":222,"activeCount":55},[],{"trials":224,"activeCount":55},[225],{"nctId":181,"briefTitle":182,"status":74,"phases":226,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":227,"interventions":228},[48],[189],[168,191,192],{"trials":230,"activeCount":55},[],{"intervention":232,"totalTrials":83,"cells":233},"Lidocaine 5% patch",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":258},{"trials":235,"activeCount":55},[],{"trials":237,"activeCount":55},[],{"trials":239,"activeCount":55},[],{"trials":241,"activeCount":55},[],{"trials":243,"activeCount":55},[244],{"nctId":245,"briefTitle":246,"status":74,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":256},"NCT04238208","The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Males With Diabetic Neuropathy",[48],"2019-12-10","2020-01-02","2019-01-10",290,[253,254,255],"Diabetic Nerve Problems","Diabetic Neuropathy","Diabetic Complications Neurological",[232,257],"Capsaicin 8% Patch, Per 10 Square Centimeters",{"trials":259,"activeCount":55},[],{"intervention":257,"totalTrials":83,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":276},{"trials":263,"activeCount":55},[],{"trials":265,"activeCount":55},[],{"trials":267,"activeCount":55},[],{"trials":269,"activeCount":55},[],{"trials":271,"activeCount":55},[272],{"nctId":245,"briefTitle":246,"status":74,"phases":273,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":274,"interventions":275},[48],[253,254,255],[232,257],{"trials":277,"activeCount":55},[],{"intervention":279,"totalTrials":83,"cells":280},"fentanyl 15 microg",{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":289,"NA":305},{"trials":282,"activeCount":55},[],{"trials":284,"activeCount":55},[],{"trials":286,"activeCount":55},[],{"trials":288,"activeCount":55},[],{"trials":290,"activeCount":55},[291],{"nctId":292,"briefTitle":293,"status":74,"phases":294,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":300},"NCT01960543","Effects of Bupivacaine and Levobupivacaine on Cerebral Oxygenation During Intrathecal Anesthesia in Elderly Patients",[48],"2014-12","2013-10",58,[299],"Complication of Anesthesia",[279,301,302,303,304],"Bupivacaine 7 mg","Bupivacaine 9 mg","Levobupivacaine 7 mg","Levobupivacaine 9 mg",{"trials":306,"activeCount":55},[],{"intervention":301,"totalTrials":83,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":323},{"trials":310,"activeCount":55},[],{"trials":312,"activeCount":55},[],{"trials":314,"activeCount":55},[],{"trials":316,"activeCount":55},[],{"trials":318,"activeCount":55},[319],{"nctId":292,"briefTitle":293,"status":74,"phases":320,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":321,"interventions":322},[48],[299],[279,301,302,303,304],{"trials":324,"activeCount":55},[],{"intervention":302,"totalTrials":83,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":341},{"trials":328,"activeCount":55},[],{"trials":330,"activeCount":55},[],{"trials":332,"activeCount":55},[],{"trials":334,"activeCount":55},[],{"trials":336,"activeCount":55},[337],{"nctId":292,"briefTitle":293,"status":74,"phases":338,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":339,"interventions":340},[48],[299],[279,301,302,303,304],{"trials":342,"activeCount":55},[],{"intervention":303,"totalTrials":83,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":359},{"trials":346,"activeCount":55},[],{"trials":348,"activeCount":55},[],{"trials":350,"activeCount":55},[],{"trials":352,"activeCount":55},[],{"trials":354,"activeCount":55},[355],{"nctId":292,"briefTitle":293,"status":74,"phases":356,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":357,"interventions":358},[48],[299],[279,301,302,303,304],{"trials":360,"activeCount":55},[],{"intervention":304,"totalTrials":83,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":377},{"trials":364,"activeCount":55},[],{"trials":366,"activeCount":55},[],{"trials":368,"activeCount":55},[],{"trials":370,"activeCount":55},[],{"trials":372,"activeCount":55},[373],{"nctId":292,"briefTitle":293,"status":74,"phases":374,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":375,"interventions":376},[48],[299],[279,301,302,303,304],{"trials":378,"activeCount":55},[],{"intervention":380,"totalTrials":83,"cells":381},"Hydrochlorothiazide and furosemide",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":404},{"trials":383,"activeCount":55},[],{"trials":385,"activeCount":55},[],{"trials":387,"activeCount":55},[],{"trials":389,"activeCount":55},[],{"trials":391,"activeCount":55},[392],{"nctId":393,"briefTitle":394,"status":156,"phases":395,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":403},"NCT01977430","Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function",[48],"2015-03","2013-11",36,[400,401,402],"Chronic Kidney Insufficiency","Hemodialysis Treatment","Diuresis Preserved",[380],{"trials":405,"activeCount":55},[],{"intervention":407,"totalTrials":83,"cells":408},"Polyethylene glycol",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":429},{"trials":410,"activeCount":55},[],{"trials":412,"activeCount":55},[],{"trials":414,"activeCount":55},[],{"trials":416,"activeCount":55},[],{"trials":418,"activeCount":55},[419],{"nctId":420,"briefTitle":421,"status":156,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":6,"conditions":425,"interventions":427},"NCT01853709","Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients",[48],"2013-12","2013-05",[426],"Bowel Preparation for Colonoscopy",[407,428],"Bisacodyl",{"trials":430,"activeCount":55},[],{"intervention":428,"totalTrials":83,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":447},{"trials":434,"activeCount":55},[],{"trials":436,"activeCount":55},[],{"trials":438,"activeCount":55},[],{"trials":440,"activeCount":55},[],{"trials":442,"activeCount":55},[443],{"nctId":420,"briefTitle":421,"status":156,"phases":444,"primaryCompletion":423,"completion":423,"start":424,"enrollment":6,"conditions":445,"interventions":446},[48],[426],[407,428],{"trials":448,"activeCount":55},[],{"intervention":450,"totalTrials":83,"cells":451},"L-BUPIVACAINE ; MORPHINE",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":471,"NA":473},{"trials":453,"activeCount":55},[],{"trials":455,"activeCount":55},[],{"trials":457,"activeCount":55},[],{"trials":459,"activeCount":55},[460],{"nctId":461,"briefTitle":462,"status":156,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":469},"NCT01825993","RANDOMISED STUDY OF EPIDURAL VS MPCA MORPHINE VS TAPP IN LAPAROSCOPIC SIGMOIDECTOMY",[47],"2015-04","2013-04",225,[468],"Sigmoidal Tumour",[450,470],"MORPHINE",{"trials":472,"activeCount":55},[],{"trials":474,"activeCount":55},[],{"intervention":470,"totalTrials":83,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":489,"NA":491},{"trials":478,"activeCount":55},[],{"trials":480,"activeCount":55},[],{"trials":482,"activeCount":55},[],{"trials":484,"activeCount":55},[485],{"nctId":461,"briefTitle":462,"status":156,"phases":486,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":487,"interventions":488},[47],[468],[450,470],{"trials":490,"activeCount":55},[],{"trials":492,"activeCount":55},[],{"intervention":494,"totalTrials":83,"cells":495},"Fendrix or HBVAXPRO 40",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":497,"activeCount":55},[],{"trials":499,"activeCount":55},[],{"trials":501,"activeCount":55},[],{"trials":503,"activeCount":55},[],{"trials":505,"activeCount":55},[],{"trials":507,"activeCount":55},[508],{"nctId":509,"briefTitle":510,"status":74,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":518},"NCT03459521","Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.",[49],"2021-08-01","2017-09-01",125,[516,517],"Liver Disease Chronic","Hepatitis B Virus",[494],{"intervention":520,"totalTrials":83,"cells":521},"Desvenlafaxine",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":532},{"trials":523,"activeCount":55},[],{"trials":525,"activeCount":55},[],{"trials":527,"activeCount":55},[],{"trials":529,"activeCount":55},[],{"trials":531,"activeCount":55},[],{"trials":533,"activeCount":55},[534],{"nctId":535,"briefTitle":536,"status":156,"phases":537,"primaryCompletion":538,"completion":538,"start":539,"enrollment":398,"conditions":540,"interventions":542},"NCT03432221","Switching From SSRI to Desvenlafaxine on Cognitive Functioning",[],"2019-06-03","2018-04-03",[541],"Major Depressive Disorder",[520],{"intervention":544,"totalTrials":83,"cells":545},"Recombinant Somatropin",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":556},{"trials":547,"activeCount":55},[],{"trials":549,"activeCount":55},[],{"trials":551,"activeCount":55},[],{"trials":553,"activeCount":55},[],{"trials":555,"activeCount":55},[],{"trials":557,"activeCount":55},[558],{"nctId":559,"briefTitle":560,"status":74,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":8,"conditions":564,"interventions":565},"NCT02205450","Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell",[],"2019-07-29","2014-09",[136],[544],{"intervention":567,"totalTrials":83,"cells":568},"Dulaglutide",{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":573,"PHASE3":575,"PHASE4":577,"NA":579},{"trials":570,"activeCount":55},[],{"trials":572,"activeCount":55},[],{"trials":574,"activeCount":55},[],{"trials":576,"activeCount":55},[],{"trials":578,"activeCount":55},[],{"trials":580,"activeCount":55},[581],{"nctId":582,"briefTitle":583,"status":74,"phases":584,"primaryCompletion":585,"completion":586,"start":249,"enrollment":587,"conditions":588,"interventions":592},"NCT04829903","Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin",[49],"2021-03-29","2021-11-20",116,[589,590,591],"Type 2 Diabetes Treated With Insulin","Obesity","Adolescent Obesity",[567,593],"Liraglutide",{"intervention":593,"totalTrials":83,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":597,"activeCount":55},[],{"trials":599,"activeCount":55},[],{"trials":601,"activeCount":55},[],{"trials":603,"activeCount":55},[],{"trials":605,"activeCount":55},[],{"trials":607,"activeCount":55},[608],{"nctId":582,"briefTitle":583,"status":74,"phases":609,"primaryCompletion":585,"completion":586,"start":249,"enrollment":587,"conditions":610,"interventions":611},[49],[589,590,591],[567,593],{"intervention":613,"totalTrials":83,"cells":614},"GH treatment",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":623,"NA":625},{"trials":616,"activeCount":55},[],{"trials":618,"activeCount":55},[],{"trials":620,"activeCount":55},[],{"trials":622,"activeCount":55},[],{"trials":624,"activeCount":55},[],{"trials":626,"activeCount":55},[627],{"nctId":628,"briefTitle":629,"status":74,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":638},"NCT06900335","Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact",[],"2025-03-15","2025-03-01",101,[635,636,637],"Prader Willi Syndrome","Hyperphagia","Behavior Disorders",[613],{"intervention":640,"totalTrials":83,"cells":641},"BRAF V600E mutation by pyrosequencing technique",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":643,"activeCount":55},[],{"trials":645,"activeCount":55},[],{"trials":647,"activeCount":55},[],{"trials":649,"activeCount":55},[],{"trials":651,"activeCount":55},[],{"trials":653,"activeCount":55},[654],{"nctId":655,"briefTitle":656,"status":74,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT02323724","APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.",[],"2015-07","2015-02",25,[662],"Papillary Thyroid Carcinoma",[640],{"intervention":665,"totalTrials":83,"cells":666},"Treatment as Usual",{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":675,"NA":677},{"trials":668,"activeCount":55},[],{"trials":670,"activeCount":55},[],{"trials":672,"activeCount":55},[],{"trials":674,"activeCount":55},[],{"trials":676,"activeCount":55},[],{"trials":678,"activeCount":55},[679],{"nctId":680,"briefTitle":681,"status":156,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":688},"NCT03128749","Mindfulness-Based Cognitive Therapy: Efficacy and fMRI-based Response Predictors in a Group of OCD Patients",[49],"2018-12","2018-01-11",60,[687],"Obsessive-Compulsive Disorder",[665],{"intervention":690,"totalTrials":83,"cells":691},"Anti-Inflammatory Agents, Non-Steroidal",{"EARLY_PHASE1":692,"PHASE1":694,"PHASE2":696,"PHASE3":698,"PHASE4":700,"NA":702},{"trials":693,"activeCount":55},[],{"trials":695,"activeCount":55},[],{"trials":697,"activeCount":55},[],{"trials":699,"activeCount":55},[],{"trials":701,"activeCount":55},[],{"trials":703,"activeCount":55},[704],{"nctId":705,"briefTitle":706,"status":74,"phases":707,"primaryCompletion":708,"completion":708,"start":709,"enrollment":685,"conditions":710,"interventions":712},"NCT02527603","Spaso Versus Self-assisted Maneuver for Anterior Shoulder Dislocation",[49],"2017-03","2015-08",[711],"Shoulder Dislocation",[690],{"intervention":714,"totalTrials":83,"cells":715},"Autologous Cytokine Rich Serum",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":717,"activeCount":55},[],{"trials":719,"activeCount":55},[],{"trials":721,"activeCount":55},[],{"trials":723,"activeCount":55},[],{"trials":725,"activeCount":55},[],{"trials":727,"activeCount":55},[728],{"nctId":729,"briefTitle":730,"status":156,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":738},"NCT04194710","Arthroscopic Debridement Versus Autologous Cytokine Rich Serum for the Treatment of Lateral Epicondylitis",[49],"2023-07-01","2023-12-01","2020-12-22",86,[737],"Epicondylitis, Lateral",[714]]